On September 21, 3SBIO rose 5.21% in regular trading, trading at 16.62 HKD/share, with turnover of approximately 97.96 million HKD.

The rally was driven by a combination of persistent share repurchases and synchronized insider and institutional accumulation. Since the beginning of September, the company has executed six buyback rounds, repurchasing a total of approximately 8.66 million shares at a combined cost of roughly 136 million HKD. Year-to-date, the company has conducted nine buyback transactions totaling approximately 271 million HKD, signaling strong management confidence in the company's intrinsic value.

Meanwhile, Chairman Lou Jing purchased 490,000 shares on September 7 at 16.0 HKD per share, while BlackRock also recently added approximately 47.6 million shares to its position, creating a resonance effect between management and institutional investors. Multiple brokerages, including Shenwan Hongyuan and CMBI, maintain bullish ratings, with the global clinical advancement of core asset SSGJ-707 in partnership with Pfizer cited as the primary upside catalyst.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)